

Australia's CSL announces expansion of US plasma therapy manufacturing facility with \$1.5 B investment

March 10, 2026 | News

Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin



CSL, an Australia-based global biopharma leader, broke ground for the expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois in the US. The expansion, a cornerstone of the company's global manufacturing growth strategy and effort to expand its US production presence, was officially announced with state and local officials, including Illinois Governor JB Pritzker, Illinois State Senator Patrick Joyce, and other key dignitaries.

The newly expanded facility will substantially increase the company's ability to produce life-sustaining, plasma-derived therapies for people living with rare and serious diseases and other acute medical issues while bringing hundreds of new, highly skilled positions to Kankakee.

This investment demonstrates CSL's commitment to its next-generation manufacturing capabilities to more efficiently meet the needs of the patient community that it treats. The Kankakee expansion, expected to be operational by 2031, will incorporate CSL's Horizon 2 manufacturing process, a patented, yield enhancing technology that enables significantly greater production of immunoglobulin from the same base amount of plasma.

This industry-leading technology is designed to improve plasma efficiency and positions CSL's US network to support sustained growth of the company's lifesaving therapies.

"Manufacturing makes the world a better place to live, and CSL is a perfect example of the impact this industry has at home and abroad. For more than a century, this innovative and dynamic company has produced life-saving medicines used across the world, and it's thrilling that they have chosen to expand their footprint in Illinois with a \$1.5 billion investment," said Mark Denzler, president & CEO of the Illinois Manufacturers' Association.